A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo
- PMID: 22689530
- DOI: 10.1158/1535-7163.MCT-12-0131
A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo
Abstract
The functional and therapeutic importance of the Warburg effect is increasingly recognized, and glycolysis has become a target of anticancer strategies. We recently reported the identification of a group of novel small compounds that inhibit basal glucose transport and reduce cancer cell growth by a glucose deprivation-like mechanism. We hypothesized that the compounds target Glut1 and are efficacious in vivo as anticancer agents. Here, we report that a novel representative compound WZB117 not only inhibited cell growth in cancer cell lines but also inhibited cancer growth in a nude mouse model. Daily intraperitoneal injection of WZB117 at 10 mg/kg resulted in a more than 70% reduction in the size of human lung cancer of A549 cell origin. Mechanism studies showed that WZB117 inhibited glucose transport in human red blood cells (RBC), which express Glut1 as their sole glucose transporter. Cancer cell treatment with WZB117 led to decreases in levels of Glut1 protein, intracellular ATP, and glycolytic enzymes. All these changes were followed by increase in ATP-sensing enzyme AMP-activated protein kinase (AMPK) and declines in cyclin E2 as well as phosphorylated retinoblastoma, resulting in cell-cycle arrest, senescence, and necrosis. Addition of extracellular ATP rescued compound-treated cancer cells, suggesting that the reduction of intracellular ATP plays an important role in the anticancer mechanism of the molecule. Senescence induction and the essential role of ATP were reported for the first time in Glut1 inhibitor-treated cancer cells. Thus, WZB117 is a prototype for further development of anticancer therapeutics targeting Glut1-mediated glucose transport and glucose metabolism.
Similar articles
-
Influence of glucose transporter 1 activity inhibition on neuroblastoma in vitro.Gene. 2019 Mar 20;689:11-17. doi: 10.1016/j.gene.2018.12.010. Epub 2018 Dec 13. Gene. 2019. PMID: 30553996
-
WZB117 (2-Fluoro-6-(m-hydroxybenzoyloxy) Phenyl m-Hydroxybenzoate) Inhibits GLUT1-mediated Sugar Transport by Binding Reversibly at the Exofacial Sugar Binding Site.J Biol Chem. 2016 Dec 23;291(52):26762-26772. doi: 10.1074/jbc.M116.759175. Epub 2016 Nov 11. J Biol Chem. 2016. PMID: 27836974 Free PMC article.
-
Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells.Oncotarget. 2015 Jan 20;6(2):651-61. doi: 10.18632/oncotarget.2892. Oncotarget. 2015. PMID: 25528771 Free PMC article.
-
The progress and development of GLUT1 inhibitors targeting cancer energy metabolism.Future Med Chem. 2019 Sep;11(17):2333-2352. doi: 10.4155/fmc-2019-0052. Future Med Chem. 2019. PMID: 31581916 Review.
-
Targeting Key Transporters in Tumor Glycolysis as a Novel Anticancer Strategy.Curr Top Med Chem. 2018;18(6):454-466. doi: 10.2174/1568026618666180523105234. Curr Top Med Chem. 2018. PMID: 29788889 Review.
Cited by
-
SLC transporters as therapeutic targets: emerging opportunities.Nat Rev Drug Discov. 2015 Aug;14(8):543-60. doi: 10.1038/nrd4626. Epub 2015 Jun 26. Nat Rev Drug Discov. 2015. PMID: 26111766 Free PMC article. Review.
-
Pheochromocytoma: Gasping for Air.Horm Cancer. 2015 Dec;6(5-6):191-205. doi: 10.1007/s12672-015-0231-4. Epub 2015 Jul 3. Horm Cancer. 2015. PMID: 26138106 Free PMC article. Review.
-
Metabolic signature identifies novel targets for drug resistance in multiple myeloma.Cancer Res. 2015 May 15;75(10):2071-82. doi: 10.1158/0008-5472.CAN-14-3400. Epub 2015 Mar 13. Cancer Res. 2015. PMID: 25769724 Free PMC article.
-
Relationship between metabolic reprogramming and drug resistance in breast cancer.Front Oncol. 2022 Aug 18;12:942064. doi: 10.3389/fonc.2022.942064. eCollection 2022. Front Oncol. 2022. PMID: 36059650 Free PMC article. Review.
-
Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib.Cancer Sci. 2015 May;106(5):567-75. doi: 10.1111/cas.12633. Epub 2015 Mar 9. Cancer Sci. 2015. PMID: 25683251 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous